March 07, 2014
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
China regulatory agency approves novel glaucoma surgical device
The China Food and Drug Administration has granted marketing approval for the IOPtiMate system developed by IOPtima., a subsidiary of BioLight Israeli Life Sciences Investments, according to a press release.
The IOPtiMate system allows eye surgeons to perform CO2 laser-assisted sclerectomy surgery, which reduces elevated IOP in glaucoma patients by thinning the sclera of the eye, which restores the natural fluid percolation without penetrating the globe, the release said.